Journal of Clinical Oncology
Articles in this Issue
Exploring the prognostic and predictive value of IL-1β, TROP2, and B7-H3 in EGFR-mutated (EGFRm) NSCLC: Insights for personalized treatment strategies.
e20680 Background: IL-1β is a pro-inflammatory cytokine linked to tumor progression and immune modulation, making it a valuable prognostic marker in NSCLC...
Healthcare provider experiences in managing antibody-drug conjugate dosing adjustments due to nausea and vomiting: SABCS and ESMO survey findings.
e13108 Background: Antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) have revolutionized breast cancer...
STARLITE-1: Phase 1b/2 study of combination <sup>177</sup> Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.
TPS4611 Background: Complete response (CR) is a rare event in advanced clear cell renal cell carcinoma (ccRCC). The combin...
Prognostic value of inflammatory markers in glioblastoma: A meta-analysis of NLR and PLR stratified by cutoff values.
2067 Background: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with an unfavorable prognosis. Identifying prognostic markers is...
Incidence and overall survival of head and neck squamous cell carcinoma in the US: SEER 17, 2018-2021.
e22564 Background: Head and neck squamous cell carcinomas (HNSCC) in the oral cavity, pharynx, and larynx represent a significant public health concern in...
Efficacy and safety of azacitidine in the treatment of elderly patients with higher-risk myelodysplastic syndromes.
e18578 Background: Hypomethylating agent Azacitidine (AZA) is standard of care for high-risk myelodysplastic syndromes (MDS). There is limited real-life d...
Assessment of OncoQuébec, an oncology clinical trials search engine, on clinical trial recruitment in Quebec.
e23110 Background: Q-CROC (Quebec-Clinical Research Organization in Cancer), a not-for-profit organization, has the mission to enhance both the knowledge...
Paraneoplastic syndromes in non-small cell lung carcinoma: A systematic review of case reports and case series.
e20041 Background: Paraneoplastic syndromes (PNS) are caused by underlying malignancy but not due to metastasis, or treatment related side effects. Studie...
Rurality and screening colonoscopy participation in patients with Lynch syndrome.
10620 Background: Lynch Syndrome (LS) is a hereditary condition that increases risk for colorectal and other primary cancers. LS arises from pathogenic va...
Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in triple-negative breast cancer: A focus on survival, metastasis, and recurrence.
e13140 Background: Triple-negative breast cancer (TNBC) is an aggressive and highly heterogeneous subtype of breast cancer. It accounts for 10–15% of all...
Summarizing utilization of integrative oncology assessments within inpatient and outpatient settings.
e23173 Background: Persons with a diagnosis of cancer are seeking innovations in cancer care. Integrative oncology (IO) utilized along with conventional c...
Association between glycemic index and glycemic load of the diet, insulin, and breast cancer: A case-control study.
e12515 Background: Despite advances in studies regarding the association between diet and the diagnosis of breast cancer, there is still controversy regar...
Improving access and communication of rural cancer patients through enhanced usage of patient portal.
e13817 Background: Oncology patients living in medically underserved areas face an increased risk of care gaps due to decreased utilization of the patient...
CD58 alterations and their role in regulating antitumor immune responses in diffuse large B-cell lymphoma.
7057 Background: Recurrent abnormalities of immune surveillance-related genes play a crucial role in DLBCL progression. Prior studies have shown that CD58...
The implication of resting natural killer cells in mesothelioma.
e20099 Background: Mesothelioma is a rare and aggressive cancer strongly associated with asbestos exposure. It is typically an incurable disease, with tre...
Demographic characteristics and survival outcomes of pediatric clear cell sarcoma of the kidney: A National Cancer Database retrospective study.
10033 Background: Clear Cell Sarcoma of the Kidney, CCSK, is a rare malignancy diagnosed during childhood. Compared to other pediatric renal neoplasms, CC...
Germline determinants of pneumonitis in patients with cancer treated with antibody drug conjugates.
12125 Background: Antibody-drug conjugates (ADCs) are now essential in the treatment of solid and hematologic cancers. While effective, ADCs can cause adv...
Tarlatamab-induced immune-related adverse events: Retrospective real-world pharmacovigilance study using FAERS database.
e24106 Background: Food and Drug Administration (FDA) approved Tarlatamab, a bispecific T-cell engager (TCE) demonstrating promising survival outcomes in...
Determinants in trimodality therapy for bladder cancer: Overcoming chemoradiotherapy resistance via ferroptosis.
4599 Background: Expanding bladder preservation therapy can improve quality of life in patients with bladder cancer. This study aims to identify genetic d...
Integrating collaborative care in oncology: Improving quality of life and mental health for patients with cancer.
1524 Background: In the U.S., 22 million patients with cancer face unmet behavioral health needs, contributing to up to $245B in preventable healthcare co...
Uptake of targeted therapy in a large cohort of patients with advanced prostate cancer and germline pathogenic variants.
5049 Background: Men with advanced prostate cancer (PrCa) and pathogenic germline variants (PGV) in homologous recombination repair (HRR) or mismatch repa...
Trial in progress: A first-in-human (FIH) phase I study of PTX-912 in patients with locally advanced or metastatic solid tumors.
TPS2694 Background: High-dose IL-2 (HD IL-2) received FDA approval for metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC), but its use is...
A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).
TPS5123 Background: Androgen receptor signaling inhibitors (ARSI), such as enzalutamide (Enza), and abiraterone (Abi), are standard therapies for metastat...
Descriptive epidemiology of gallbladder cancer (GBC): Real-world clinical characteristics and outcomes of patients in the US community oncology setting.
e16248 Background: GBC is a rare malignancy, marked by significant heterogeneity in presentation and outcomes between locally advanced (LA) and advanced (...
Impact of a molecular tumor board on treatment decisions for advanced solid tumors: Experience from a Portuguese cancer center.
e23343 Background: Molecular Tumor Boards (MTB) are pivotal in precision oncology. For patients with advanced solid tumors, after conventional therapeutic...